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Abstract 
Dengue fever is now endemic in over 100 countries and over 2.5 billion people are 
at risk for infection each year. Due to the adaptive nature of the mosquito vectors, the 
number of geographically affected areas continues to rise at an accelerated rate. While 
most of the infected survive the conventionally high fever associated with Dengue, some 
progress into the severely critical period marked by hemorrhage and hypovolemic shock.  
If intense clinical care is not taken, this form of dengue can be fatal. Five known serotypes 
exist for dengue, but cross-reactive antibodies that cause antibody-dependent viral 
enhancement in secondary infection provide unique challenges in vaccine development. 
Recent studies have shown promising results against viruses belonging to the same family 
as dengue, with the use of pyrazine carboximide antivirals T-705 and T-1106 that serve as 
inhibitors of viral RNA-dependent RNA polymerase in rodent models. It is with 
consideration of these results that an efficacy comparison of T-705 and T-1106 treatment 
for Dengue virus in a rodent model it proposed.  
 
 
 
 
 
 
 
 
 
 
Introduction 
Dengue Virus (DENV) is a +sense single stranded RNA virus and a member of the 
Flaviviridae family of viruses that also include West Nile virus (WNV) and yellow fever 
virus (YFV). Dengue virus has 4 known serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), 
with a 5th serotype (DENV-5) purportedly discovered in 2013 (3, 7, 8). Transmission of DENV 
to humans and non-human primates occurs through its intermediate vector, mosquitoes 
Aedes aegypti and Aedes albopictus, which can be found throughout the world (1, 2). Dengue 
virus is considered a significant threat to public health on a global scale with an estimated 
390 million infections per year and more than 500,000 cases resulting in severe, potentially 
fatal forms of the disease (1, 3, 6). Contraction of the virus is known to cause dengue fever 
(DF) as well as the more severe manifestations of dengue hemorrhagic fever (DHF) and 
dengue shock syndrome (DSS). Although dengue is an old disease, with some literature 
suggesting outbreaks dating back to 900 AD, prior to 1970 only 9 countries had been 
known to have severe epidemics. Incidence of infection has not only been rising rapidly in 
recent years, but unprecedented outbreaks are occurring in entirely new areas; Dengue is 
now endemic in more than 100 countries (4, 9, 19).  
 The scope this research proposal focuses on potential post-infection treatment of 
dengue by comparative exploration of antiviral drugs that have demonstrated improved 
immunological activity in treating other RNA viruses in rodent models (12, 13, 14, 15, 16, 17). The 
goal of the experiment is to show similarly improved immunological activity in dengue-
infected rodents, serving as a preliminary tool for potential future human treatments.  The 
antiviral treatments work by inhibiting RNA-dependent RNA polymerase, an essential 
protein encoded by all RNA viruses that enable viral replication. 
Transmission & Characteristics 
 DENV propagates between humans and mosquitoes in a circular pattern of 
transmission. The cycle begins when the female mosquito feeds on a DENV infected human 
host, then subsequently on a healthy human (10). When the mosquito first becomes infected, 
the virus incubates for a period of 4 to 10 days, growing in the mosquito gut, and later 
migrating to the salivary glands. Once a mosquito becomes infected it is capable of 
transmitting the virus for the remainder of its life . Humans serve as the primary carrier 
and multipliers of the virus, providing an easily accessible reservoir for mosquito 
transmission (4).  
While some remain asymptomatic, DENV infection most often results in dengue 
fever. Symptoms of infection proceed in 3 phases: fever phase, critical period (DHF/DSS 
development), and recovery phase. The fever phase is characterized by high fever (104 oF), 
nausea, vomiting, malaise, myalgia, retro-orbital headache, and arthralgia, and typically 
lasts for 3-10 days. Most patients pass from the fever phase into the recovery phase, but if 
severe drop in platelet count is detected, patients are often monitored for DHF 
development. The onset of the critical period is observed between 3-7 days after initial 
symptoms, lasting for 24-48 hours, and is initially characterized by reduced fever (100oF). 
The distinction of DHF/DSS is capillary leakage coinciding with cytokine storm, 
thrombocytopenia, and intestinal hemorrhage. If increased fluid leakage is not countered 
with appropriate fluid intake, DSS hypovolemic shock will occur and the patient must be 
monitored for mucosal, skin, and rectal bleeds. Careful monitoring is imperative for 
survival and procession to the recovery phase. Recovery phase is 2-4 days following the 
critical period and patients’ improvement is immediately apparent. Notably, if patients 
were inundated with excess fluid replacement during the preceding critical period, heart 
failure or pulmonary edema can manifest during the recovery phase, thus too much fluid 
loss or replacement during the critical phase are equally dangerous and can lead to death (4, 
14, 21).  
 
Immunization & Treatment 
 A culmination of several factors enhances the public threat posed by dengue. A. 
aegypti is a daytime feeder most active at dawn and dusk, capable of consuming multiple 
blood meals from a number of hosts at each feeding, while A. albopictus is known to be 
highly adaptive. Its ability to tolerate freezing temperatures and adapt to various 
environments has enabled its accelerated spread throughout the world. Although 
prevention measures, such as limiting standing water near urban areas, the use personal 
protection such as clothing coverings, screens, and insecticide treatments etc., are helpful 
and recommended,  prevailing socioeconomic factors are often inhibitory to appropriate 
Dengue prevention and control measures. Presently, there are no vaccines for DENV, 
although research is ongoing (4, 21). 
 
Pathogenicity Challenges 
 DENV vaccine developers face unique challenges with Dengue requiring a vaccine 
that must immunize against all known serotypes (14). While infection with one serotype, can 
provides long term immunity to that serotype, cross-reactive antibodies generated in the 
initial infection serve as a means of enhancement in subsequent infection by a different 
serotype (19).  
 During the initial infection, with for example DENV-1 serotype, DENV-1 antibodies 
are produced, completely binding the viral envelope and preventing viral binding of the 
cognate receptor. The antibodies mediate endocytosis into the cell through Fc-receptors, 
initiating lysosomic response that prevents envelope conformational change required for 
endosomal breach and subsequent release of the RNA genome into the cytoplasm, allowing 
it to be effectively neutralized. During a secondary infection by another serotype, for 
example DENV-2, B cell immunological memory DENV-1 antibodies are dispatched because 
of perceived virion similarity, but only weakly bind the DENV-2 envelope, leaving it 
unneutralized. The DENV-2 virion is then able not only to bind it’s cognate receptor for cell 
entry, but the sparsely bound antibodies mediate an additional means of cell entry through 
the Fc-receptor. Albeit, because the antibodies are only sparsely bound to the viral 
envelope, the envelope is unrestrained from executing its conformational change and is 
then able to release its genome into an unsuspecting, unprepared compartment of the cell. 
This phenomenon is known as antibody-dependent enhancement (ADE) and is directly 
associated with severe dengue manifestations such as DHF and DSS (5, 20).  
 In addition to ADE, anomalous T cell response and viral virulence factors also 
contribute to severity of DENV pathogenesis. In secondary infection with disparate 
serotypes, cross-reactive T Cells have been found to release an excess of pro-inflammatory 
cytokines resulting in the endothelial dysfunction that produces vascular leakage along 
with abnormal apoptosis activity and of inefficient anti-DENV specific response (21). DENV 
is a competent virus that has evolved an array of virulence factors allowing it to 
simultaneously evade host immune response and expand viral replication. While vaccines 
are the principle aegis against viral infections, the acute degree of pathogenicity possessed 
by DENV supports the imperative for antiviral research and development.  
 
Research Objective & Activity in Other Viral Models 
The Flaviviridae family, that includes over 70 viruses, consists of single stranded, 
positive sense, enveloped, RNA genomes primarily spread though arthropod vectors.  
yellow fever (YFV), West Nile (WNV), and Japanese encephalitis (JEV) viruses are members 
of this family and along with DENV, are primarily spread through mosquito vectors (18, 22, 
23). Widespread morbidity and potential for viral hemorrhagic fevers have encouraged 
great research efforts on how best to inhibit their pathogenicity through antivirals.  
 In one such study conducted by the Institute for Antiviral Research at Utah State 
University, a pyrazine carboximide, dubbed T-705, was found to provide mortality 
protection, reduced viral load and reduced viral protein expression in rodents challenged 
with subcutaneous WNV administration (13). Prior studies had shown effective antiviral 
activity of T-705 against Influenza strains A, B and C, as well as against viruses belonging to 
the bunyaviridae and arenavirus families, respectively (12,15,16). The mechanism of action for 
T-705 was explored against influenza by Furuta et al., and found to inhibit influenza’s RNA-
dependent RNA polymerase (Rdrp) function (12). While the mechanism of action in Morrey, 
Futura et al.’s WNV T-705 study was not conclusively confirmed (17), the broad-spectrum 
efficacy of T-705 and mechanism identified in the Futura et. al study makes it an eligible 
candidate for DENV treatment exploration (12, 16, 17). 
 Another pyrazine carboxamide, T-1106, was the subject of a study against YFV, 
undertaken by Julander et al. en vitro, both T-705 and T-1106 were tested in Vero cells, but 
results showed only weak activity (13). Interestingly, when tested in a rodent model, T-1106 
showed significant efficacy, reducing viral load and vastly improving mortality rates 
against YFV (16).  
 With the various studies done on both T-1106 and T-705 and their RdRp inhibition 
properties that have been met with impressive in vivo results in Flaviviridae, as well as 
other RNA virus models, an efficacy comparison of T-705 and T-1106 treatment for DNV in 
a rodent model is the target of this proposal. Exploration of this Rdrp-targeted DENV 
treatment could provide additional insight to the intricate virulence factors DENV 
possesses, other modes of activity of T-1106 and T-705 in an in vivo rodent model for 
DENV, as well as the advancement of DENV antiviral research toward the consummate goal 
of human treatment.  
 
Experimental Design  
 My hypothesis is that T-705 and T-1106 will impair the activity of DENV RdRp by 
acting as GTP-competitive inhibitor as observed in other Flaviviridae rodent models (16). By 
doing an efficacy comparison, we may be able to show which treatment would be most 
worthy of further anti-DENV research development.  
 DENV receptive BALB/c mice (anticipated weight near 20g) will be obtained. After a 
24-hour quarantine and 1-week acclimation period, a first group of mice will be DENV 
challenged by injection to determine both viral lethal dose and appropriate virus dilution 
for the experiment. Once these initial parameters have been defined, mice will be divided 
into 3 main groups: T-705 group (TG5), T-1106 group (TG6) and a placebo group (TPG) 
that will serve as a control group. Experimental group 1 (EG1) will consist of selected mice 
from the TG5 and TG6 group that will be administered their respective antiviral 4 hours 
before DENV challenge, then daily thereafter for 7 days. Among this group there will be a 
division of oral administration (EG1O) and peritoneal inoculation (EG1P), each of which 
will have further group divisions based on the following dosages: 50/mg/kg/day, 200 
mg/kg/day, and 400 mg/kg/day (13).  
 Two additional experimental groups will be established (EG2, EG3), also consisting 
of selected mice from TG5 and TG6. EG2 will follow the model of EG1 except that mice will 
first undergo a DENV challenge, foregoing respective antiviral administration until day 2. 
EG3 will similarly follow the model of EG1, but forego antiviral administration until day 4. 
The TPG group will be divided into positive and negative control groups. TPG1, the positive 
control group, will follow the drug administration models of EG1, EG2, and EG3, both oral 
and peritoneal, but will be not be DENV challenged. TPG2, the negative control group, will 
be DENV challenged but administered placebo antivirals in parallel with administration 
protocol of groups EG1, EG2, and EG3, respectively (Figure 1).  
Viral loads and platelet counts will be tested at 6 hour intervals to track antiviral 
response. Selected mice from each group and corresponding subgroup will be euthanized 
at various intervals to explore T cell, various other immune cell counts as well as 
histopathology images.  
An attempt will be made to explore DHF/DSS development and the effects of T-705 
and T-1106 treatment 4 weeks post-recovery of surviving mice by subsequent DENV 
challenge with divergent serotype. Experimental groups will be set up as before unless the 
initial experimental results require experimental design adjustments.  
This experimental design consisting of different variable alteration groups and sub-
groups will allow a comprehensive comparative analysis of DENV progression and antiviral 
effectiveness through data analysis of morbidity, mortality, and recovery rates as well as 
viral loads, cell, and platelet counts.  
 
Anticipated Results and Interpretation 
 While DENV virus shares many similarities with WNV and YVF, it is possible that 
these pyrazine carboxamide will not show the same level of effectiveness for RdRp 
inhibition or general viral load reduction as seen in other Flaviviridae rodent models. Host 
enzyme reduction of pyrazine carboxamide derivatives  into metabolite 
ribfuranosyltriphosphate is thought to be the mechanism of action that inhibits viral Rdrp, 
yet is not shown to disturb host DNA & RNA synthesis in WNV and YVF models. Virulence 
factors uniquely possessed by DENV, but not yet realized could interfere with this 
mechanism. Despite this possibility, the need for DENV antiviral development, combined 
with the promising results seen for T-705 and T-1106 in previous rodent models, makes 
this proposal a necessary avenue for exploration (21). It is anticipated that data analysis will 
indeed reveal novel anomalies not seen in other viral models due to the unique 
pathogenicity and virulence factors of DENV. It is further anticipated that remarkable 
evolutionary conservation of viral RdRps, especially within respective RNA polarity groups, 
will allow DENV RdRp disruption similarly observed in WNV and YFV pyrazine 
carboximide studies (11). The prospect of this novel data and potential contribution to the 
understanding of DENV in vivo will be an invaluable contribution to understanding 
pathogen activity and host interaction in vivo. 
  
Conclusion 
Today, 2.5 Billion people, or 40% of the world’s population, live in Dengue epidemic 
regions. With the accelerated worldwide dissemination and high-adaptability of A. aegypti 
and A. albopictus, combined with socioeconomic restrictions on mosquito prevention and 
control, alternative solutions to DENV response need to be explored (4, 6, 21). While a Dengue 
vaccine would be ideal, the challenge posed by varying serotypes and their cooperative 
pathogenic enhancement is prohibitive and post-infection antiviral treatment would still 
serve as a very useful tool in battling Dengue outbreaks. A key innovation on the road to 
human antiviral and anti-DENV treatment is an effective mouse model that allows for 
disease attribute exploration as well as testing of promising therapeutic solutions (21). It is 
the aim of this proposal to serve such functions and contribute to the body of knowledge of 
both the virological and overall scientific communities. It is through models such as this, 
that the prospect for effective human antiviral therapies come one step closer to realization 
and the outlook for DENV becomes optimistic. 
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Figure 1. Experimental design mice groupings schematic 
 
